ニュース

ABOUT AINOS NEWS
Search by year or by keyword :
Date Title
2022-05-12 Ainos新型ウィルス抗原検査キット寄贈式
2021-12-07 Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection
2021-11-03 Ainos SRNA Research Initiative Announces Milestones for mRNA Vaccine Development
2021-08-16 Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives
2021-06-14 Ainos Named Exclusive Sales Partner for COVID-19 Antigen Rapid Test Kit in Taiwan
2021-05-24 Ainos Announces FINRA Approval of Name Change and Ticker Symbol Change to "AIMD", Engages Firm to Explore Listing Requirements of National Securities Exchanges
2021-04-21 Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
2020-12-30 Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth.
2020-09-10 Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board.
2020-08-13 Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics.
CONTACT US

アメリカ合衆国:

8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108

 +1 (858) 869-2986


台湾:

新竹県竹北市生医五路66号10F-2

 +886 (0)3-550-5199

COMPANY

製品

AI 電子鼻

低用量経口インターフェロン

合成 RNA

ニュース

個人情報保護

INVESTORS

株主・投資家情報

株価情報

IRトピックス

コーポレート・ガバナンス

事業報告書

IRメール配信

OUR AGENTS

INABATA & CO., LTD.

元又興業股份有限公司

Copyright © 2023 Ainos Inc. All rights reserved.